Preclinical Behavioral Pharmacology Testing

The contract is for preclinical behavioral pharmacology testing aimed at evaluating the abuse liability of drugs through standardized experiments in non-human animal models. It specifically involves conducting fixed-ratio dose-effect studies and behavioral economic demand curve analyses to measure how drug availability and cost influence consumption patterns, providing critical data on reinforcement and motivational properties. These experiments follow established protocols to generate reliable, reproducible outcomes that inform regulatory assessments of drug potential for misuse. This is a subcontract under an 8(a) Sole Source acquisition, designated for small disadvantaged businesses, with the North American Industry Classification System code 541710 indicating it falls under scientific research and development services. The solicitation was posted by the FDA Office of Acquisition Grant Services within the Department of Health and Human Services, with a response deadline of August 4, 2026. The work is expected to be performed under the authority of the contracting agency, though the specific location of performance is not detailed. The contract supports federal efforts to evaluate pharmaceutical safety and inform public health policy through rigorous preclinical behavioral science.